blog

print rss Bookmark and Share

HDMA Track and Trace Technology Seminar - A Snapshot

Written By: Peter Monahan

Wednesday, December 16, 2009

I recently attended the HDMA Trace and Trace Technology seminar in MD. It was my first HDMA seminar, and even though attendance was down from previous years, it was a great opportunity to catch up with many existing TraceLink customers.



The focus of the seminar was on serialization and EPCIS much more than ePedigree. The general feeling seems to be that if an organization can tackle the serialization/EPCIS challenges that lay ahead, then pedigrees should follow on relatively easily. To an extent, I can see this point as many of the underlying technologies and some of the processes are shared between the domains. Yet, based on the work that we did back at SupplyScape on the harmonization of serialization/EPCIS/ePedigree, much depends on the definition of 'pedigree' and the specific use cases that you want to support in business operations. If serialization and EPCIS efforts push towards "point in time authentication" rather than end-to-end chain of custody, there will still be much work to do to incorporate the pedigree model.

Here are my takeaways from the sessions and coffee break discussions:

Pedigree Regulations
Not much has changed regarding pedigree regulations. There have been a few changes to some of the state regulations (e.g. CO delayed to 2017), but for the most part, it is status quo. In discussions, most people seem to think that the FDA will eventually develop nationwide regulations that are relatively close to the CA regulations. Unfortunately, the representative from the FDA did not seem ready to discuss the issue in any great detail at the event and did not offer any particularly new insights. I suspect there might have been a desire to keep a low profile given the policy tug of war going on in Washington. However, he did use the term “centralized database” at one point when speaking about technologies, which became a talking point in a few follow-on discussions that I participated in.

CA Compliance Readiness
While in the past, much of the serialization discussion in the U.S. centered on California, today, the majority of the serialization efforts among manufacturers are occurring in Europe, not in the U.S. As a result, U.S. based serialization vendors are shifting personnel to Europe or partnering with local companies to meet demand.

In an interesting case of financial tug-of-war, supply chain operational departments seem to be struggling to get budget for serialization pilots in 2010 when the CA regulations are still 5-6 years away even though they expect it to take multiple years to achieve full CA compliant serialization in production. A familiar refrain from those who have limited pilots in place to those who don’t is: “better get started soon or you won’t make it”.

This leaves open the question of tying the two threads together. Work is going on in Europe and resources are being shifted there yet initiatives in the U.S. are being starved. One would like to say that the European projects are a good testing ground for the requirements of CA and perhaps Federal initiatives. Yet, knowing the unique technical and process challenges in Europe, my take is: Don’t bet on it!

Interoperability Challenges
The industry as a whole continues to struggle with the interoperability of the various available technologies. The roundtable discussion regarding serial number aggregation, inference and data management drew large groups who engaged in some vibrant debates.

Heather Zenk from AmerisourceBergen, who is a licensed pharmacist, brought the plight of the pharmacist to the forefront. With so many technologies being discussed, tested and piloted, organizations need to make sure that they do not forget the pharmacist at the end of the line who may not necessarily be technically savvy and who cannot be expected to support a different technology from each vendor. These questions arise at every step in the supply chain, although in my experience the pharmacy has to deal with the added complexity of supporting the “pharmacist bench” along with the normal receiving and internal distribution processes.

The industry, regulatory bodies and standards orgs clearly have their work cut out to define acceptable approaches to provide full end-to-end product traceability.

GS1 2015 Readiness Program
One item that I heard a fair number of people discussing is the GS1 2015 Readiness Program that Bob Celeste announced. GS1 plans to simulate serialized products moving through the supply chain to help organizations gain valuable experience without having to spin up full trading partner pilots. Follow this link for more information.

All in all, it was a good event although you could feel the reticence of the audience in truly committing towards any one initiative. Perhaps understandable after the past few years of "hurry up and wait". The unfortunate thing is that this cycle will probably continue until more clarity is provided on many fronts.

AMR Healthcare Exchange an Evergreen Opportunity for Value

Written By: Shabbir Dahod

Tuesday, December 01, 2009

 I recently attended the AMR Healthcare Exchange and I walked away with a feeling of Déjà vu. First of all, Hussain Mooraj and the AMR team do a great job of stimulating ideas and connections for joint value creation at all ends and aspects of the supply chain, including pharmaceutical, life sciences and health care participants. As always there was a clear sense of urgency and a feeling of lost time and missed opportunities. This was accentuated by the closing remarks by Johnson and Johnson (J&J) President of Supply Chain and Business Processes, Tom Sullivan. Tom outlined the major value opportunities attained by CPG that remain distant goals for the Healthcare industry. His challenge to the industry was to do for life saving drugs and devices what we do for Coke cans.

This year’s conference provided case studies of value attainment by connecting providers into a Demand-Driven Supply Network (DDSN) of Pharmaceutical and BioTech companies. Roddy Martin made the case for Patient Outcomes as the Moment of Truth for the Healthcare value chain. From the presentations it was clear that significant value attainment was possible when companies collaborated to identify and understand each others business issues and in turn develop mutual trust to enhance integrated cross-company business processes for shared and measurable value.

The frustration and excitement for all of us is the sheer volume of opportunity and the feeling that four years ago we were discussing the same opportunities. Because other industries dominate the annual Top 25 Supply Chain list, Healthcare needs its own special list of Healthcare Top 25 to identify the leaders in this lagging industry. However, our industry has complexity and dynamics that require greater care and hence can support change in very measured steps. These steps need more investment and oversight in our industry.

As an entrepreneur by nature and profession, I am an optimist! In my first job in the summer 1981, between high school and college, I worked for an entrepreneur who was starting a company to provide Local Area Networking (LAN) gear. In doing research for him I was so excited by the fact that he was entering a market at a time when market data identified the 1980’s as the Network Decade. As years and decades past, I was told that every year was the breakthrough year and every decade was the Network Decade. Now it is clear that networking is an endless source of value which grows exponentially as it matures.

DDSN is the same class of evergreen opportunity and the Healthcare industry is transforming to leverage the value from integrating processes, people and information. The strategic imperatives in all parts of the value chain require greater network integration for the next level of financial performance. We work across the value chain and it is obvious to us that business plans more so than regulatory force will drive the adoption of supply network solutions.

Please share with me your perspective. Are you as optimistic as I am and what parts of the supply chain do you see collaborating more effectively?